Health
Cervical cancer a threat for lesbian, bi women
Women urged to get tested for HPV


Human Papilloma Virus (HPV) (Photo public domain)
LONDON — Lesbian and bi women are urged to get tested for the human papillomavirus (HPV) because of its connection to cervical cancer, health experts are saying to mark Jo’s Cervical Cancer Trust’s Cervical Screening Awareness Week this week.
An article in Gay Star News, a UK-based LGBT news agency, said any woman with an intact cervix who is sexually active (gay or straight) should have regular cervical screenings. The HPV virus is spread through skin-to-skin contact.
There are particular problems with lesbian and bi women accessing cervical screening, the article said.
Stonewall Research, which polled about 6,000 lesbian and bisexual women, found they were often excluded from routine testing for cervical cancer. The Stonewall survey also these women were reluctant to be honest about their sexual orientation with health care professionals as they feared stigma and discrimination.
Research by the Lesbian and Gay Foundation, carried out with the University of Salford between 2010 and 2013, looked at the barriers experienced by lesbian and bi women attending cervical screening. Many women said they had been wrongly advised they did not need screening and some had even been refused screening as they only had female partners. Women respondents also said health care professionals had asked inappropriate questions or had wrongly assumed they were straight, Gay Star News reported.
Almost all the women (93 percent) said health care professionals needed more training on the needs of lesbian and bi women.
Health
Gilead awards $5 million grant to HRC’s HIV and health equity programs
Money to support efforts to end the epidemic and combat stigma

The Human Rights Campaign was awarded a $5 million grant from drugmaker Gilead Sciences to expand the organization’s HIV and health equity programs, supporting efforts to end the HIV epidemic by 2030 while combatting stigma in Black and Latino communities.
Funds will be used over the next three years for the HRC Foundation’s HIV and Health Equity Program, its Historically Black Colleges and Universities Program, and its Transgender Justice Initiative, HRC said in a statement Wednesday announcing receipt of the award, which extends Gilead’s $3.2 million grant to the HRC Foundation in 2021.
The organization said its HIV and Health Equity Program plans to develop a “benchmarking tool for institutions that provide HIV services, helping better evaluate the quality of care and measure racially and socially inclusive approaches” while defining “best practices, policies and procedures to optimize HIV service provision for BIPOC LGBTQ+ communities.”
HRC President Kelley Robinson said, “Since the beginning of the HIV epidemic, racism and anti-LGBTQ+ discrimination have created dangerous hurdles for those seeking prevention or treatment.”
“With the generous support of Gilead Sciences, we’ll be able to continue providing critical
resources to help overcome these hurdles, especially focusing on Black and Latine communities in the U.S. South,” Robinson added. “We’ll also be able to expand our efforts, as we seek to remove institutional barriers often unknowingly created by HIV service providers. We must decrease the disparities that place an unnecessary burden on Black and Latine LGBTQ+ people and people living with HIV.”
Gilead Executive Vice President of Corporate Affairs and General Counsel Deborah Telman said the company “is committed to advancing health equity, particularly in Black communities and other communities of color that are disproportionately affected by HIV.”
“This grant will build on the impactful work HRC has done with community partners and HBCUs to increase awareness of HIV treatment and prevention options and reduce health disparities, combat discrimination and fight stigma,” Telman said.
Health
New CDC data shows HIV infections dropped, but mostly among whites
Socioeconomic factor into disproportionate rates

Data published Tuesday by the Centers for Disease Control and Prevention shows a significant decline in new HIV infections, but suggests the impact of prevention efforts was far less substantial for Black and Latino populations.
From 2017-2021, as rates of HIV testing, treatment and the use of pre-exposure prophylaxis (PrEP) medication rose, new cases dropped by 12 percent overall and by as much as 34 percent among gay and bisexual males aged 13-24.
The numbers show a “move in the right direction,” CDC Director Rochelle Walensky said in a press release.
However, when broken down by race, the CDC found new infections were down by 27 percent and 36 percent, respectively, among Black and Latino populations, compared with 45 percent of whites.
Similarly, by 2021 about one third of those who are considered eligible were taking PrEP for HIV prevention, but the CDC noted this number includes “relatively few Black people or Hispanic/Latino people” despite the significant increase in prescriptions up from just 13 percent in 2017.
“Longstanding factors, such as systemic inequities, social and economic marginalization and residential segregation,” Walensky noted, continue to act as barriers “between highly effective HIV treatment and prevention and people who could benefit from them.”
She added, “Efforts must be accelerated and strengthened for progress to reach all groups faster and equitably.”
Robyn Neblett Fanfair, acting director of the CDC’s Division of HIV Prevention, said that “At least three people in the U.S. get HIV every hour — at a time when we have more effective prevention and treatment options than ever before.”
“These tools must reach deep into communities and be delivered faster to expand progress from some groups to all groups,” she said.
The HIV+Hepatitis Policy Institute issued a press release following the CDC’s announcement of the new data, noting both the encouraging progress and need for improvement.
“It appears that our investments in HIV prevention are providing some positive results, but the persistent high number of new diagnoses and the low usage of PrEP among the communities most impacted by HIV point to the need for increased resources, particularly for a national PrEP program,” said the group’s executive director, Carl Schmid.
President Joe Biden’s FY24 budget requested $237 million for a national PrEP program along with $850 million to support the U.S. Department of Health and Human Services’ “Ending the HIV Epidemic in the U.S.” initiative.
Health
Officials eye mpox prevention, vaccination initiatives for this summer’s LGBTQ events
New cluster of cases reported in Chicago

Federal health agencies, in coordination with their state and local counterparts and community partners, are exploring opportunities to offer mpox prevention initiatives and vaccinations at LGBTQ events this summer, Dr. Demetre Daskalakis said on Thursday.
Daskalakis, the deputy coordinator for the White House’s national mpox response, described these deliberations in response to a question from the Washington Blade during a media telebriefing on mpox that was hosted by the Centers for Disease Control and Prevention.
The CDC on Monday issued a Health Alert Network Health Update on the potential risk for new mpox cases.
Since the peak of about 460 cases per day in August 2022, new cases have steadily declined, but following the cluster recently reported in the Chicago area, the update warns, “spring and summer season in 2023 could lead to a resurgence of mpox as people gather for festivals and other events.”
“We have the vaccine, and we have organizations that are willing to do it,” Daskalakis said during Thursday’s call, adding that resources are available and can be deployed flexibly because they are built into existing “HIV and STI funding to allow for this work.”
And the Mpox Crisis Response Cooperative Agreement, Daskalakis said, “provides even more resources locally for such efforts.”
Daskalakis and CDC Mpox Response Incident Manager Dr. Christopher R. Braden also briefed reporters on findings from new studies on the efficacy of the JYNNEOS vaccine for the prevention of mpox.
That data, per the CDC’s Morbidity and Mortality Weekly Report, reveals that “Among gay, bisexual, and other MSM and transgender adults aged 18-49 years, two doses of the JYNNEOS vaccine were 86 percent effective against mpox, indicating substantial protection against mpox.”
Additionally, “All routes of vaccine administration provided similar protection.”
-
Politics4 days ago
Elon Musk pledges to lobby for criminalizing healthcare interventions for transgender youth
-
Texas4 days ago
Texas governor signs bill banning transgender youth healthcare
-
Florida5 days ago
Gay Days 2023 will go on despite DeSantis and anti-LGBTQ animus
-
Middle East4 days ago
Upwards of 30,000 march in Jerusalem Pride parade
-
U.S. Federal Courts4 days ago
Federal judge rules Tenn. drag ban is unconstitutional
-
Photos2 days ago
PHOTOS: GMCW’s “Dolly”
-
European Union4 days ago
Latvia elects first openly gay president
-
National4 days ago
LGBTQ literature advocacy org to host celebrity panel